ArticleSpringerPlus2015
Antibacterial activity of nineteen selected natural products against multi-drug resistant Gram-negative phenotypes.
Article in SpringerPlus, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Appraising the therapeutical potentials ofFrontiers in pharmacology · 2022Pooled it
- The GenusMolecules (Basel, Switzerland) · 2026Review
- Antibacterial Activity of Extract, Fractions, and Compounds fromPharmaceuticals (Basel, Switzerland) · 2026Article
- Role of hydrogen sulfide in bacterial antibiotic tolerance: from mechanisms to therapeutic targeting.Frontiers in cellular and infection microbiology · 2026Review
- Prevalence and effective treatment of drug-resistant Pseudomonas aeruginosa biofilm using flavonoid naringin.Bioprocess and biosystems engineering · 2025Article
- A comprehensive computer-based assessment of Deacetylnomilin as an inhibitor for antibiotic-resistant genes identified from the whole genome sequence of the multidrug-resistant Enterobacter cloacae isolate 1382.Molecular diversity · 2025Article
- Bixin fromACS omega · 2025Article
- Highlighting the Potential of LyeTx I, a Peptide Derived from the Venom of the SpiderPharmaceuticals (Basel, Switzerland) · 2025Article
- Article
- Reviewing the Therapeutic Potential of Plant-based Natural Products against Multidrug-resistant Bacteria (MDR).Current drug research reviews · 2025Review
- Manniosides G-J, New Ursane- and Lupane-Type Saponins fromMolecules (Basel, Switzerland) · 2024Article
- Production of kojic acid by Aspergillus flavus OL314748 using box-Behnken statistical design and its antibacterial and anticancer applications using molecular docking technique.BMC microbiology · 2024Article
- Antibacterial Activity and Mechanisms of Plant Flavonoids against Gram-Negative Bacteria Based on the Antibacterial Statistical Model.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Medicinal plant Miconia albicans synergizes with ampicillin and ciprofloxacin against multi-drug resistant Acinetobacter baumannii and Staphylococcus aureus.BMC complementary medicine and therapies · 2023Article
- Antibacterial and anti-biofilm activity of plumbagin against multi-drug resistant clinical bacterial isolates.Saudi medical journal · 2022Article
- Anti-Biofilm and Associated Anti-Virulence Activities of Selected Phytochemical Compounds againstPlants (Basel, Switzerland) · 2022Article
- Thiophenes-Naturally Occurring Plant Metabolites: Biological Activities and In Silico Evaluation of Their Potential as Cathepsin D Inhibitors.Plants (Basel, Switzerland) · 2022Review
- Tackling Multiple-Drug-Resistant Bacteria With Conventional and Complex Phytochemicals.Frontiers in cellular and infection microbiology · 2022Review
- Improvement of cytotoxicity of mitoxantrone and daunorubicin by candidone, tephrosin, and bavachinin.Molecular biology reports · 2021Article
- Chemical Composition and Antimicrobial Activity of a New Olive Pomace Functional Ingredient.Pharmaceuticals (Basel, Switzerland) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The present study was designed to assess the antimicrobial activity of 19 natural products belonging to terpenoids, alkaloids, thiophenes and phenolics against a panel of 14 Gram-negative multidrug-resistant (MDR) bacteria. The results demonstrated that amongst the studied compounds, alkaloids and terpenoids were less active contrary to flavonoids: neocyclomorusin (3) and candidone (6) and isoflavonoids: neobavaisoflavone (8) and daidzein (12). Thiophene, 2-(penta-1,3-diynyl)-5-(3,4-dihydroxybut-1-ynyl)thiophene (17) showed moderate and selective activities. Compounds 3, 6, 8 and 12 displayed minimal inhibitory concentration (MIC) ranged from 4 to 256 μg/mL on all the 14 tested bacteria. MIC values below 10 μg/mL were obtained with 8, 3, 6 and 12 against 50, 42.9, 35.7 and 21.4 % of the tested bacteria. The lowest MIC value of 4 μg/mL was obtained with compound 3 against Klebsiella pneumoniae ATCC11296, Enterobacter cloacae BM47, compound 6 against Escherichia coli ATCC8739, K. pneumoniae ATCC11296, E. cloacae BM47 and compound 8 against K. pneumoniae ATCC11296 and E. cloacae BM47. The activity of flavonoid 3 was better or equal to that of chloramphenicol in all tested K. pneumoniae, Providencia stuartii, E. aerogenes, E. cloacae and Pseudomonas aeruginosa strains. Within isoflavonoids, neobavaisoflavone scaffold was detected as a pharmacophoric moiety. This study indicates that natural products such as 3, 6 and 8 could be explored more to develop antimicrobial drugs to fight MDR bacterial infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.